Human papillomavirus vaccination and Pap testing profile in Manitoba, Canada

Vaccine

Volumn 32, Issue 1, 2013, Pages 33-38

  Kliewer, Erich V ^a,b,c   Mahmud, Salaheddin M ^a,b   Demers, Alain A ^a,b   Lambert, Pascal ^a  

^a Epidemiology and Cancer Registry   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Cervical cancer; Human papillomavirus (HPV); Pap test; Screening; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CANADA; CANCER REGISTRY; CANCER SCREENING; CERVICAL CANCER ELECTRO OPTICAL SENSOR; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VACCINATION; YOUNG ADULT;

CERVICAL CANCER; HUMAN PAPILLOMAVIRUS (HPV); PAP TEST; SCREENING; VACCINATION;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; FEMALE; HUMANS; MANITOBA; MIDDLE AGED; ODDS RATIO; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POPULATION SURVEILLANCE; REGISTRIES; RETROSPECTIVE STUDIES; VACCINATION; VAGINAL SMEARS; YOUNG ADULT;

EID: 84891928282     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.082     Document Type: Article

References (31)

1. Schiller J.T., Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004, 2(4):343-347.
2. Haug C.J. Human papillomavirus vaccination-reasons for caution. N Engl J Med 2008, 359(8):861-862.
3. Herzog T.J., Huh W.K., Downs L.S., Smith J.S., Monk B.J. Initial lessons learned in HPV vaccination. Gynecol Oncol 2008, 109(2 Suppl):S4-S11.
4. Kulasingam S., Connelly L., Conway E., Hocking J.S., Myers E., Regan D.G., et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health 2007, 4(3):165-175.
5. Adams M., Jasani B., Fiander A. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. Vaccine 2007, 25(16):3007-3013.
6. Anic G.M., Lee J.H., Villa L.L., Lazcano-Ponce E., Gage C., Jose C.S.R., et al. Risk factors for incident condyloma in a multinational cohort of men: the HIM study. J Infect Dis 2012, 205(5):789-793.
7. Brisson M., Drolet M., Malagon T. Inequalities in human papillomavirus (HPV)-associated cancers: Implications for the success of HPV vaccination. J Nat Cancer Inst 2013, 105(3):158-161.
8. Drolet M., Boily M.C., Greenaway C., Deeks S.L., Blanchette C., Laprise J.F., et al. Sociodemographic inequalities in sexual activity and cervical cancer screening: implications for the success of human papillomavirus vaccination. Cancer Epidemiol Biomarkers Prev 2013, 22(4):641-652.
9. Saslow D., Wheeler C.M. Human papillomavirus vaccines: who will pay, who will receive, when to administer?. Ethn Dis 2007, 17(Suppl 2). S2-8-13.
10. Franco E.L., Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008, 26(Suppl 1):A16-A23.
11. Kliewer E.V., Demers A.A., Brisson M., Severini A., Lotocki R., Elias B., et al. The Manitoba human papillomavirus vaccine surveillance and evaluation system. Health Rep 2010, 21(2):37-42.
12. Manitoba Cervical Cancer Screening Program Operations & statistical report 2005 and 2006 2008, CancerCare Manitoba, Winnipeg.
13. Manitoba Cervical Cancer Screening Program Screening guidelines 2010, CancerCare Manitoba, Winnipeg.
14. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Fox B., Scholar S., et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vac 2011, 7(12):1359-1373.
15. Malagon T., Drolet M., Boily M.C., Franco E.L., Jit M., Brisson J., et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12(10):781-789.
16. Schiller J.T., Castellsague X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(Suppl 5):F123-F138.
17. Roteli-Martins C.M., Naud P., De Borba P., Teixeira J.C., De Carvalho N.S., Zahaf T., et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vac Immunother 2012, 8(3):390-397.
18. Rowhani-Rahbar A., Alvarez F.B., Bryan J.T., Hughes J.P., Hawes S.E., Weiss N.S., et al. Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine. J Clin Virol 2012, 53(3):239-243.
19. National Advisory Committee on Immunization Statement on human papillomavirus vaccine: an Advisory Committee Statement (ACS). Can Commun Dis Rep 2007, 33(ACS-2):1-32.
20. Saslow D., Castle P.E., Cox J.T., Davey D.D., Einstein M.H., Ferris D.G., et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007, 57(1):7-28.
21. Kulasingam S.L., Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003, 290(6):781-789.
22. Brotherton J.M., Mullins R.M. Will vaccinated women attend cervical screening? A population based survey of human papillomavirus vaccination and cervical screening among young women in Victoria, Australia. Cancer Epidemiol 2012, 36(3):298-302.
23. Juraskova I., Bari R.A., O'Brien M.T., McCaffery K.J. HPV vaccine promotion: does referring to both cervical cancer and genital warts affect intended and actual vaccination behavior?. Womens Health Issues 2011, 21(1):71-79.
24. Mather T., McCaffery K., Juraskova I. Does HPV vaccination affect women's attitudes to cervical cancer screening and safe sexual behaviour?. Vaccine 2012, 30(21):3196-3201.
25. Kuitto K., Pickel S., Neumann H., Jahn D., Metelmann H.R. Attitudinal and socio-structural determinants of cervical cancer screening and HPV vaccination uptake: a quantitative multivariate analysis. J Public Health 2012, 18:179-188.
26. Anhang Price R., Koshiol J., Kobrin S., Tiro J.A. Knowledge and intention to participate in cervical cancer screening after the human papillomavirus vaccine. Vaccine 2011, 29(25):4238-4243.
27. Cooke R., French D.P. How well do the theory of reasoned action and theory of planned behaviour predict intentions and attendance at screening programmes? A meta-analysis. Psychol Health 2008, 23(7):745-765.
28. Franco E.L., Cuzick J., Hildesheim A., de Sanjose S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006, 24(Suppl 3):S171-S177.
29. Kim J.J., Goldie S.J. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008, 359(8):821-832.
30. Chao C., Velicer C., Slezak J.M., Jacobsen S.J. Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. Am J Epidemiol 2010, 171(3):357-367.
31. Jemal A., Simard E.P., Dorell C., Noone A.M., Markowitz L.E., Kohler B., et al. Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Nat Cancer Inst 2013, 105(3):175-201.